1. Home
  2. BH vs SVRA Comparison

BH vs SVRA Comparison

Compare BH & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biglari Holdings Inc. Class B

BH

Biglari Holdings Inc. Class B

HOLD

Current Price

$296.56

Market Cap

1.2B

ML Signal

HOLD

SVRA

Savara Inc.

HOLD

Current Price

$5.20

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BH
SVRA
Founded
1934
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
BH
SVRA
Price
$296.56
$5.20
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$7.33
AVG Volume (30 Days)
153.8K
1.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$597.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$195.05
$1.89
52 Week High
$483.60
$7.01

Technical Indicators

Market Signals
Indicator
BH
SVRA
Relative Strength Index (RSI) 31.71 40.72
Support Level $269.96 $5.10
Resistance Level $319.42 $6.10
Average True Range (ATR) 21.72 0.28
MACD -5.12 -0.05
Stochastic Oscillator 5.46 11.00

Price Performance

Historical Comparison
BH
SVRA

About BH Biglari Holdings Inc. Class B

Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Share on Social Networks: